Ovid Therapeutics
OVID • NASDAQ
Ovid Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Margaret Alexander, with a market cap of $347.4M.
CEOMargaret Alexander
Next Earnings
Upcoming earnings announcement for Ovid Therapeutics
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.12
Revenue Estimate
$65.0K
Earnings History
Past 12 earnings reports for Ovid Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Q4 2025 | $0.06Est: -$0.10 | +160.0% | $718.0KEst: $133.6K | +437.6% | — |
| Nov 12, 2025 | Q3 2025 | -$0.17Est: -$0.15 | -13.3% | $132.0KEst: $238.2K | -44.6% |  10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.06Est: -$0.15 | +60.0% | $6.3MEst: $115.1K | +5350.1% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.14Est: -$0.13 | -7.7% | $130.0KEst: $33.3K | +290.0% | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.13Est: -$0.17 | +23.5% | $76.0KEst: $187.5K | -59.5% | 10-K/A |
| Nov 12, 2024 | Q3 2024 | -$0.20Est: -$0.19 | -5.3% | $173.0KEst: $87.1K | +98.5% | 10-Q |
| Aug 13, 2024 | Q2 2024 | $0.12Est: -$0.22 | +154.5% | $169.0KEst: $70.0K | +141.4% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.17Est: -$0.22 | +22.7% | $148.0KEst: $60.0K | +146.7% | 10-Q |
| Mar 8, 2024 | Q4 2023 | -$0.22Est: -$0.05 | -340.0% | $141.6KEst: $60.0K | +135.9% | 10-K |
| Nov 3, 2023 | Q3 2023 | -$0.16Est: -$0.19 | +15.8% | $109.0KEst: $50.0K | +117.9% | — |
| Aug 4, 2023 | Q2 2023 | -$0.18Est: -$0.20 | +10.0% | $75.0KEst: $50.0K | +50.0% | 10-Q |
| May 5, 2023 | Q1 2023 | -$0.19Est: -$0.17 | -11.8% | $66.2KEst: $20.0K | +230.8% | — |